Burkitt lymphoma
Conditions
Brief summary
2-year PFS; defined as time from randomisation to disease progression, relapse or death, whichever comes first. Patients still alive or lost to follow up are censored at the date they were last known to be alive
Detailed description
ORR end-of-treatment, EFS at 2 years; defined as time from randomisation to first event (death from any cause, no CR, relapse, whichever comes first)., OS at 2 years; defined as time from randomisation until death from any cause; patients still alive or lost to follow up are censored at the date they were last known to be alive, Rate of CTCAE grade ≥3 toxicities, Number of hospitalization days
Interventions
DRUGMETHOTREXATE
DRUGIFOSFAMIDE
DRUGVINCRISTINE
DRUGCYCLOPHOSPHAMIDE
DRUGRITUXIMAB
DRUGETOPOSIDE
DRUGCYTARABINE
DRUGPREDNISOLONE
DRUGDOXORUBICIN
Sponsors
Haemato Oncology Foundation For Adults Netherlands
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year PFS; defined as time from randomisation to disease progression, relapse or death, whichever comes first. Patients still alive or lost to follow up are censored at the date they were last known to be alive | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR end-of-treatment, EFS at 2 years; defined as time from randomisation to first event (death from any cause, no CR, relapse, whichever comes first)., OS at 2 years; defined as time from randomisation until death from any cause; patients still alive or lost to follow up are censored at the date they were last known to be alive, Rate of CTCAE grade ≥3 toxicities, Number of hospitalization days | — |
Countries
Belgium, Netherlands
Outcome results
None listed